Barrett's Esophagus with Esophageal Adenocarcinoma, Submucosal Invasion (T1b), and High-Risk Tumor Histology

This protocol addresses a specific, high-stakes presentation of Barrett's esophagus: esophageal adenocarcinoma (EAC) that has penetrated into the submucosa (T1b stage) and carries high-risk histological features — meaning it does not qualify as low-risk (i.e., it lacks superficial sm1 invasion, a negative deep margin, well-to-moderate differentiation, and absence of lymphovascular invasion). The combination of submucosal invasion and high-risk histology substantially elevates the likelihood of lymph node involvement, which drives the management approach.

Clinical Scenario

Patient presents with T1b esophageal adenocarcinoma arising in Barrett's esophagus. Histology confirms at least one high-risk feature — such as deeper submucosal invasion, positive or indeterminate deep margin, poor differentiation, or presence of lymphovascular invasion — ruling out low-risk classification. This scenario carries a high risk of regional lymph node metastases and requires escalated management beyond endoscopic options.

Management Direction

For patients in this category, the recommended pathway involves surgical evaluation. The protocol specifies the appropriate surgical referral pathway and outlines when multidisciplinary discussion may be warranted to consider alternatives for patients who are not surgical candidates.

The complete structured regimen — including specific criteria, referral pathway, and alternative considerations — is available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.14309/ajg.0000000000001680

Esophagectomy has traditionally been recommended in patients with EAC with submucosal invasion (T1b EAC) given the high risk of lymph node metastases.
Patients with high-risk histology are best treated with esophagectomy, unless the patient is a poor surgical candidate, for whom discussion at a multidisciplinary conference may be appropriate to consider alternative options such as adjuvant chemoradiation.

View source ↗